Dynavax Technologies Revenue Growth Rates (DVAX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dynavax Technologies Corporation  (NASDAQ: DVAX)
 

DVAX's Revenue Growth by Quarter and Year

Dynavax Technologies's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DVAX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 94.88
2nd Quarter June 95.44
1st Quarter March 68.16
FY 258.48

DVAXs Annual Revenue
Dynavax Technologies's Revenue in the fiscal year 2024 $ 277.25 millions
Dynavax Technologies's Revenue in the fiscal year 2023 $ 231.28 millions
Dynavax Technologies's Revenue in the fiscal year 2022 $ 721.68 millions
Dynavax Technologies's Revenue in the fiscal year 2021 $ 438.44 millions
Dynavax Technologies's Revenue in the fiscal year 2020 $ 39.70 millions




DVAX Revenue third quarter 2025 Y/Y Growth Comment
Dynavax Technologies Corporation reported Revenue increase of 17.67% year on year in the third quarter 2025, to $ 94.88 millions, this is lower than Dynavax Technologies Corporation's recent average Revenue surge of 251.27%.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue growth. While Dynavax Technologies Corporation' s Revenue growth of 17.67% ranks overall at the positon no. 1110 in the third quarter 2025.


DVAX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 29.55 % -69.86 % -5.42 %
3rd Quarter September 17.67 % 17.69 % -59.16 % 56.37 %
2nd Quarter June 29.32 % 22.49 % -76.42 % 384.1 %
1st Quarter March 34.2 % 8.23 % -58.83 % 36.78 %
FY   - 19.87 % -67.95 % -

Financial Statements
Dynavax Technologies's third quarter 2025 Revenue $ 94.88 millions DVAX's Income Statement
Dynavax Technologies's third quarter 2024 Revenue $ 80.63 millions Quarterly DVAX's Income Statement


DVAX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -10.67 % -18.84 % 9.99 %
3rd Quarter September -0.59 % 9.25 % 13.71 % -34.34 %
2nd Quarter June 40.02 % 45.3 % 28.38 % 124.11 %
1st Quarter March -5.37 % -8.65 % -74.56 % -41.56 %
FY (Year on Year)   - 19.87 % -67.95 % -


Back to DVAX Growth rate Comparisons >> Back to DVAX Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #177
Overall #1110

Revenue Y/Y Growth Statistics
High Average Low
3913.37 % 251.27 % -96.9 %
(Mar 31 2019)   (Dec 31 2017)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #177
Overall #1110
Revenue Y/Y Growth Statistics
High Average Low
3913.37 % 251.27 % -96.9 %
(Mar 31 2019)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Dynavax Technologies's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
685.71 % 49.05 % -97.64 %
(Mar 31 2018)  


DVAX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2025 Dynavax Technologies Corporation disclosed decrease in Revenue from the second quarter by -0.59% to $ 94.88 millions, from $ 95.44 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Dynavax Technologies's Revenue growth quarter on quarter, overall rank is 1447.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #206
Overall #1447
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #206
Overall #1447
Revenue Q/Q Growth Statistics
High Average Low
685.71 % 49.05 % -97.64 %
(Mar 31 2018)  


DVAX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2025 Dynavax Technologies Corporation disclosed decrease in Revenue from the second quarter by -0.59% to $ 94.88 millions, from $ 95.44 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Dynavax Technologies's Revenue growth quarter on quarter, overall rank is 1447.


Dynavax Technologies's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 330.51 $ 316.27 $ 294.62 $ 277.25 $ 260.81
Y / Y Revenue Growth (TTM) 26.73 % 27.17 % 25.29 % 19.87 % -27.59 %
Year on Year Revenue Growth Overall Ranking # 3212 # 2430 # 1188 # 1613 # 3142
Seqeuential Revenue Change (TTM) 4.5 % 7.35 % 6.27 % 6.3 % 4.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 1673 # 1455 # 728 # 1583 # 2678


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Dynavax Technologies's cumulative twelve months Revenue were $ 331 millions, company would post below average annual Revenue growth of 4.87% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Dynavax Technologies's Revenue growth from the 95.44% growth in Jun 30 2025.

In the Healthcare sector 426 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2430 to 3212.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 427
Overall # 3212

Revenue TTM Y/Y Growth Statistics
High Average Low
3913.37 %
 251.27 %
-96.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 266
S&P 500 # 1673
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Dynavax Technologies's cumulative twelve months Revenue were $ 331 millions, company would post below average annual Revenue growth of -96.9% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Dynavax Technologies's Revenue growth from the 95.44% growth in Jun 30 2025.

In the Healthcare sector 426 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2430 to 3212.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 427
Overall # 3212

Revenue TTM Y/Y Growth Statistics
High Average Low
3913.37 %
251.27 %
-96.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 266
S&P 500 # 1673




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DVAX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Electrocore Inc 30.53%$ 30.529 millions
Irhythm Holdings Inc 30.27%$ 30.273 millions
Xoma Royalty Corporation29.93%$ 29.929 millions
Precipio inc 29.91%$ 29.910 millions
Insulet Corporation29.86%$ 29.858 millions
Immunocore Holdings Plc29.22%$ 29.216 millions
Ceribell Inc 28.99%$ 28.987 millions
Harmony Biosciences Holdings inc 28.90%$ 28.903 millions
Neurocrine Biosciences Inc 27.78%$ 27.777 millions
Intelligent Bio Solutions Inc 27.46%$ 27.458 millions
Talkspace Inc 27.37%$ 27.370 millions
Lightwave Logic Inc 27.27%$ 27.274 millions
Koru Medical Systems Inc 27.17%$ 27.166 millions
The Pennant Group Inc 26.76%$ 26.759 millions
Grail Inc 26.32%$ 26.323 millions
Rigel Pharmaceuticals Inc25.59%$ 25.594 millions
Addus Homecare Corp25.07%$ 25.073 millions
Pro dex Inc 24.43%$ 24.429 millions
Nephros Inc 24.33%$ 24.325 millions
Viemed Healthcare Inc 23.98%$ 23.981 millions
Medpace Holdings Inc 23.74%$ 23.736 millions
Axogen inc 23.51%$ 23.514 millions
Sanara Medtech Inc 23.11%$ 23.115 millions
Globus Medical Inc 22.91%$ 22.909 millions
Intuitive Surgical Inc 22.89%$ 22.891 millions
Regenxbio Inc 22.88%$ 22.879 millions
Zomedica Corp 22.71%$ 22.706 millions
Invo Fertility Inc 22.60%$ 22.604 millions
Sanuwave Health Inc 22.34%$ 22.340 millions
Aveanna Healthcare Holdings Inc 22.18%$ 22.183 millions


About Dynavax Technologies Revenue Growth Rates (DVAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dynavax Technologies Corp (CIK 1029142).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-049536
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dynavax Technologies Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.